Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025

Reuters

Sep 05, 2025

Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025

Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2565715554"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565715554\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565715554?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565715554","market":"us","top_or_hot":-1,"title":"Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-05 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1113","symbol_name":"化肥与农用药剂","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL551jfl:1","article_id":"2565715554","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565715554","pubTimestamp":1757069212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1113":"化肥与农用药剂","BK0009":"债转股","BK0250":"批发","BK0116":"体育","BK0028":"国家队","BK0013":"天津自贸区","BK0074":"参股金融","000652":"泰达股份","08189":"泰达生物"},"translate_title":"天津泰达生物医药报告综合营业额增长7.01%，2025年上半年录得亏损人民币6.4百万元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000652":0.9,"08189":0.9},"content_text":"Tianjin TEDA Biomedical Reports 7.01% Increase in Consolidated Turnover, Records RMB6.4 Million Loss for H1 2025\n    \n\n        Tianjin TEDA Biomedical Engineering Co. Ltd. reported its unaudited half-yearly results for the six months ended June 30, 2025. The company achieved a consolidated turnover of RMB226.4 million, marking a 7.01% increase from the RMB211.6 million recorded during the same period in 2024. The consolidated gross profit for the period was RMB13.8 million, up by 14.07% compared to RMB12.1 million in the previous year. However, the company reported a loss attributable to equity owners amounting to RMB6.4 million, which is a larger loss compared to the RMB4.1 million recorded in the corresponding period of 2024. The company did not recommend the payment of dividends for the six months ending June 30, 2025. Tianjin TEDA is primarily engaged in the biological compound fertilizer business, focusing on products that support the balanced growth of grains, fruit, and vegetables.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}